Pfizer To Face Securities Fraud Suit Over Celebrex
Pfizer Inc. is back in the hot seat in a securities fraud class action accusing a company it acquired in 2003 of making materially false statements about a clinical study of...To view the full article, register now.
Already a subscriber? Click here to view full article